Phase III brings the emergence of adolescent sexuality and of the subject's first sustained encounter with mood- and performance-modifying substances. Neither domain is left unmanaged. The Office's pharmacopornographic protocol specifies the channels through which both domains will be introduced, the registers in which they will be presented, and the data the Office will collect from the subject's engagement with each.
The premise is unchanged from earlier Phases: an unmanaged adolescent domain generates affective surplus that the Office's instruments cannot capture. A managed domain generates surplus the Office can capture, route, and convert. The pharmacopornographic protocol exists because adolescent sexuality and adolescent substance-engagement are the two most volatile and highest-yield affect-domains in the lifecycle.
First sexual encounter, in the Office's published guidance, should occur through platform-mediated channels. The platform's affordances make the encounter measurable, the consent terms standardized, the affective payload archivable, and the subject's preference profile encodable for downstream Phase-IV partner-matching markets. Subjects who encounter sexuality outside the platform register operate outside the Office's data envelope; the Office records the disengagement and notes it on the Phase-III profile.
The platform delivers a curated continuum of erotic content scaled to the subject's developmental stage and affective parameters. The continuum is calibrated to produce the subject's lifelong preference baseline, which persists into Phase-V reproductive transfer with minimal re-tuning. The Office considers this Phase-III deliverable to be among its most consequential.
The Office publishes a substance schedule for Phase III. Substances on the schedule have an Office-certified distribution channel, an approved indication, and a published outcome profile. Substances off the schedule are not available through Office-certified channels; subjects who acquire them through informal channels operate outside the published outcome envelope and assume the calibration cost.
| class | substance | indication | channel |
|---|---|---|---|
| A | Focus Enhancer (FE) | attentional steadiness < cohort median × 2 Q | school nurse / Form 9-A |
| B | Mood Stabilizer (MS) | Mood Stability Index < 6.0 × 1 Q | school nurse / Form 9-B |
| C | Sleep Regulator (SR) | circadian drift > 90 min from cohort norm | OTC / OHCOSE-certified |
| C | Hormonal Modulator (HM) | Phase-V transfer readiness check | endocrinology referral |
| D | Recreational (RC-Lic.) | social-cohort integration support | Office-licensed venue · age 17+ |
Tbl. 3.4.A — Phase-III Substance Schedule (extract, rev. 33.7)
The Office's longitudinal evidence indicates that a Phase-III cohort prescribed Class-A focus enhancers at age fifteen performs measurably better on the Phase-IV economic-onboarding indicators than a cohort entering Phase IV unmedicated. The Office accordingly recommends the Class-A introduction at the age-fifteen review meeting for any subject whose Phase-III attentional steadiness has registered below cohort median for two consecutive quarters.
Caregivers may opt out on Form 9-Q. Opt-out is recorded on the subject's profile and accrues to a downstream Phase-IV onboarding-friction adjustment. The Office does not adjudicate the opt-out; it documents the trajectory that follows.